From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Respiratory tract infections are a major health problem worldwide. Streptococcus pneumoniae remains the most prevalent respiratory tract pathogen. Because of the increasing prevalence of antibiotic resistance in S pneumoniae and other respiratory tract pathogens, development of new antibacterials has become necessary to treat infections that no longer respond to commonly used agents. Telithromycin, a ketolide, is a potent new oral agent designed to treat community-acquired respiratory tract infections and is especially effective against S pneumoniae strains that are resistant to penicillins and macrolides.
Carter
Peggy L
PL
University of Michigan College of Pharmacy, Ann Arbor, 48106-1065, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D048628:Ketolides / Q000494:pharmacology / Q000627:therapeutic use*; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D018570:Risk Assessment; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin